Radiolabelled 68Ga/18F prostate-specific membrane antigen (PSMA) PET-CT is increasingly used in imaging prostate cancer. However, PSMA SPECT-CT imaging might be a useful alternative in nuclear medicine departments where access to PSMA-PET-CT imaging is limited. The clinical uses of SPECT tracers in the management of PCa are increasingly explored and the evidence is evolving in several clinical scenarios.
Objectives
- To review potential role of 99mTc-PSMA SPECT-CT imaging in prostate cancer
- Review current evidence and clinical roles in both diagnostic and therapeutic setting
Intended Audience
Nuclear Medicine and oncology professionals including Urologists, Physicians, Surgeons, Nuclear Medicine Technologists, Radiographers, Nurses, Physicists, healthcare professionals who specialise in Nuclear Medicine, Oncology and treating patients with radionuclide therapies.
2 CPD points
Watch the video and complete the online self-reflection form. Go to "My events" to download your certificate. You must login to watch the video and receive CPD.